Case Reports in Endocrinology · Published 2025-01-01 · DOI 10.1155/crie/4553039
Conclusion: Although, rare reports of hypercalcemia induced by discontinuation of denosumab are primarily seen in adolescents. By reporting this case, we aim to alert clinicians to the risk of rebound hypercalcemia in adult patients with FD undergoing denosumab treatment.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →